- In Memoriam
- Foreword to the First Edition
- Preface to the Second Edition
- Preface to the First Edition
- Contributors
- IBiological Bases of Pediatric Psychopharmacology
- II Somatic Interventions
- III Assessment and Treatment
- 31 Assessment and Treatment of Attention-Deficit Hyperactivity Disorder
- 32 Assessment and Treatment of Child and Adolescent Depressive Disorders
- 33 Assessment and Treatment of Childhood and Adolescent Bipolar Disorder
- 34 Assessment and Treatment of Child and Adolescent Anxiety Disorders
- 35 Assessment and Treatment of Obsessive-Compulsive Disorder
- 36 Assessment and Treatment of Tourette Syndrome and Other Tic Disorders
- 37 Assessment and Treatment of Early-onset Schizophrenia Spectrum Disorders
- 38 Assessment and Treatment of Autistic and Other Pervasive Developmental Disorders
- 39 Assessment and Treatment of Post-traumatic Stress Disorder
- 40 Assessment and Treatment of Eating Disorders and Obesity
- IV Epidemiological, Research, and Methodological Considerations
- 49 Pediatric Psychopharmacoepidemiology: Who Is Prescribing? And For Whom, How, and Why?
- 50 Clinical Trials Methodology and Designs
- 51 Regulatory Issues
- 52 Ethical Issues in Pediatric Psychopharmacology
- 53 Conflict of Interest
- 54 International Patterns of Pediatric Medication for Emotional and Behavioral Disorders
- Appendix: Psychopharmacology at a Glance
- Disclosures of Financial Interests
- Index
Assessment and Treatment of Autistic and Other Pervasive Developmental Disorders
- Chapter:
- Assessment and Treatment of Autistic and Other Pervasive Developmental Disorders
- Author(s):
Christopher J. McDougle
and David J. Posey
- DOI:
- 10.1093/med/9780195398212.003.0038
"Chapter 38 defines the five subtypes of PDD included in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIV-TR) (American Psychiatric Association 2000) and discusses the differential diagnosis of PDDs, followed by aspects of clinical assessment and evaluation, measurement of symptom severity and change, reviews the results from drug treatment studies, with a focus on more recent controlled trials, and presents ideas for future directions of research ."
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- In Memoriam
- Foreword to the First Edition
- Preface to the Second Edition
- Preface to the First Edition
- Contributors
- IBiological Bases of Pediatric Psychopharmacology
- II Somatic Interventions
- III Assessment and Treatment
- 31 Assessment and Treatment of Attention-Deficit Hyperactivity Disorder
- 32 Assessment and Treatment of Child and Adolescent Depressive Disorders
- 33 Assessment and Treatment of Childhood and Adolescent Bipolar Disorder
- 34 Assessment and Treatment of Child and Adolescent Anxiety Disorders
- 35 Assessment and Treatment of Obsessive-Compulsive Disorder
- 36 Assessment and Treatment of Tourette Syndrome and Other Tic Disorders
- 37 Assessment and Treatment of Early-onset Schizophrenia Spectrum Disorders
- 38 Assessment and Treatment of Autistic and Other Pervasive Developmental Disorders
- 39 Assessment and Treatment of Post-traumatic Stress Disorder
- 40 Assessment and Treatment of Eating Disorders and Obesity
- IV Epidemiological, Research, and Methodological Considerations
- 49 Pediatric Psychopharmacoepidemiology: Who Is Prescribing? And For Whom, How, and Why?
- 50 Clinical Trials Methodology and Designs
- 51 Regulatory Issues
- 52 Ethical Issues in Pediatric Psychopharmacology
- 53 Conflict of Interest
- 54 International Patterns of Pediatric Medication for Emotional and Behavioral Disorders
- Appendix: Psychopharmacology at a Glance
- Disclosures of Financial Interests
- Index